Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.55 |
| ▸ | CCR3 | P51677 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957283 | 0.89 | SSTR5 (0.63) | KMT2AMCHR1CCR3DRD4SSTR5 | |
| SCHEMBL2953829 | 0.81 | MCHR1 (0.71) | MCHR1DRD4LMNASIGMAR1 | |
| SCHEMBL2962996 | 0.81 | SSTR5 (0.60) | KMT2AMCHR1CCR3DRD4SSTR5 | |
| SCHEMBL2960441 | 0.79 | SSTR5 (0.59) | KMT2AMCHR1CCR3SSTR5KCNH2 | |
| SCHEMBL2954283 | 0.79 | SSTR5 (0.65) | KMT2AMCHR1CCR3DRD4SSTR5 | |
| SCHEMBL2957381 | 0.78 | SSTR5 (0.64) | KMT2AMCHR1CCR3SSTR5KCNH2 | |
| SCHEMBL2955901 | 0.78 | SSTR5 (0.79) | KMT2AMCHR1CCR3SSTR5KCNH2 | |
| SCHEMBL2963928 | 0.78 | KMT2A (0.50) | KMT2AMCHR1CCR3DRD4SIGMAR1 | |
| SCHEMBL2954727 | 0.78 | SSTR5 (0.67) | CCR3SSTR5KCNH2 | |
| SCHEMBL2955372 | 0.77 | MCHR1 (0.65) | MCHR1DRD4LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | KMT2A 3271/4885MCHR1 97/4885CCR3 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.